ClinicalTrials.gg
RecruitingNCT07470788Updated Aug 19, 2026

FIH ITA Study - Vesalius TMVr System for Symptomatic Degenerative Mitral Regurgitation

An interventional study of Transcatheter Mitral Valve Repair in Degenerative Mitral Regurgitation, sponsored by Vesalius Cardiovascular Inc.. Recruiting at 1 site in Canada. Open to participants aged 19 Years and older. Per ClinicalTrials.gov, last updated 2026-08-19.

Sponsored by Vesalius Cardiovascular Inc. · Not applicable, Interventional, and Device feasibility

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
5
Allocation
Not applicable
Ages
19 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 47 studies in Mitral Valve Insufficiency with a site in Canada — 10 open to participants now, 23 under way, 1 of them phase 3. Mitral Valve Insufficiency · Canada.

Planned enrollment
32nd of 35
5 · median 130
Started
2026
with 1 other
No phase
26 of 47
7 open now
Primary completion
2032-04
later than 22 of 22 live
Registered
46th of 47
by date

Among the 47 studies in Mitral Valve Insufficiency with a site in Canada, this one is the 32nd largest by planned enrollment of the 35 interventional ones that give a count, is one of 2 that started in 2026, is one of 26 with no phase, reaches primary completion later than 22 of the 22 other live ones, and was the 46th registered.

Mitral Valve Insufficiency

471 studies on the registry are indexed under Mitral Valve Insufficiency; 165 are open to participants now.

Browse Mitral Valve Insufficiency studies →

Open to participants now

10 of the 47 studies in Mitral Valve Insufficiency with a site in Canada are open now. Recruiting first, the newest first:

4 more — sign in →

All 10 open studies →

A study can be open while its sites in Canada have not opened yet or have stopped. Only those recruiting at a site in Canada →

Who these studies take

Of the 121 Mitral Valve Insufficiency studies recruiting now, 100 (83%) set no upper age limit and 6 (5%) stop at 75 or younger; 12 take children under 18; 1 takes healthy volunteers.

This study: 19 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 47 studies in Mitral Valve Insufficiency with a site in Canada, or all of them as a file.
02

Study summary

This first-in-human study evaluates the safety and performance of the Vesalius Transcatheter Mitral Valve Repair (TMVr) System in patients with degenerative mitral regurgitation. The study will enroll patients who are at high or prohibitive risk for conventional surgical repair or replacement of the mitral valve. Participants will receive implantation of the Vesalius TMVr System and will be followed to assess clinical outcomes, device performance, and any adverse events.

Read the detailed description

This first-in-human study is designed to evaluate the safety and performance of the Vesalius Transcatheter Mitral Valve Repair (TMVr) System in patients with symptomatic, severe or moderate-to-severe degenerative mitral regurgitation who are at elevated surgical risk. The study will enroll up to five patients in Canada to assess procedural feasibility, technical performance, and short-term clinical outcomes following device implantation. Endpoints are based on Mitral Valve Academic Research Consortium (MVARC) definitions, including measures of procedural and device success, freedom from major adverse events, and technical achievement of device deployment. Safety, functional, and hemodynamic parameters will be monitored at predefined intervals, and follow-up will include assessment of valve function, adverse events, and device performance. This study will provide preliminary data to support the further development and evaluation of the Vesalius TMVr System.

03

Conditions studied

  • Degenerative Mitral Regurgitation
04

Who can participate

Ages eligible
19 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Age ≥ 19 years
  2. Moderate to severe (≥3+) or severe (≥4+) degenerative mitral valve regurgitation (per American Society of Echocardiography (ASE) guidelines, depicted in Figure 14)
  3. (NYHA) Functional Class II, III, or Ambulatory (IV)
  4. Elevated risk for surgical mitral valve repair: Society of Thoracic Surgery (STS) predicted risk of mortality (PROM) of ≥6% as determined by the STS Risk Calculator for Surgical Repair of Primary Mitral Regurgitation [1], as well as patient operative risk assessment by the Heart Team
  5. Suitable anatomy for the Vesalius TMVr System as determined by pre-procedure imaging
  6. Willing to adhere to study follow-up schedule for up to 5 years
  7. Written provided

Exclusion criteria

Exclusion Criteria:

  1. Anatomy ideally suitable for other approved transcatheter therapy (i.e. TEER candidate)
  2. LV \< 30%
  3. Active bacterial endocarditis within 60 days of planned index procedure
  4. Dialysis-dependent renal insufficiency
  5. (BMI) ≥ 45 kg/m2
  6. Previous valvular surgery
  7. Previous atrial septal surgery
  8. Previous endovascular structural procedure(s) and/or device(s) within 6 months
  9. Severe mitral annular calcification (MAC) prohibiting device implantation
  10. Severe annulus or leaflet calcification
  11. Leaflet perforation
  12. to anticoagulation / antiplatelet therapy
  13. Patients with sensitivity to nickel or contrast media
  14. Concomitant severe tricuspid regurgitation
  15. Absence of conventional medial and lateral papillary muscle groups
  16. Femoral vein cannot accommodate a 29 F catheter
  17. Contraindication to Transoesophageal echocardiography (TEE)
  18. \<1 year due to non-cardiac comorbidities.
  19. Presence of other anatomic, comorbid conditions, or other medical conditions that could limit the subject's ability to participate in the clinical investigation or to comply with follow-up requirements, or impact the scientific soundness of the clinical investigation results, in the opinion of the Heart Team
  20. Participation in other clinical investigation
  21. Pregnant or planning to become pregnant
Terms in these criteria, in plain language(6)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

LVEF (left ventricular ejection fraction)

The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

05

Study design

Phase
Not applicable
Primary purpose
Device feasibility
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
5 participants (estimated)

Study arms

  • Experimental
    Vesalius TMVr System

    Participants in this arm will undergo implantation with the Vesalius Transcatheter Mitral Valve Repair (TMVr) System according to the study protocol. All procedures will be performed by trained interventional cardiologists, and participants will be followed for safety, device performance, and clinical outcomes at predefined intervals.

    Device: Transcatheter Mitral Valve Repair

Interventions

  • DeviceTranscatheter Mitral Valve Repair

    The Vesalius Transcatheter Mitral Valve Repair (TMVr) System is a novel transcatheter device designed to percutaneously deliver an implant to repair the native mitral valve in patients with degenerative mitral regurgitation. The system uses an adjustable ePTFE net to reduce or eliminate mitral regurgitation. The device is delivered via a minimally invasive transcatheter approach, allowing precise positioning and deployment in high-risk patients not suitable for conventional surgery.

06

What researchers measure

Primary outcomes

  1. Safety - Number of Participants Experiencing All-Cause Mortality

    Number of participants experiencing all-cause mortality post-implant, prior to discharge, and through the 30-day follow-up period.

    Time frame: 30 Days

  2. Number of Participants Achieving Technical Success

    Number of participants achieving successful delivery and positioning of the device, absence of procedural mortality, and freedom from emergency cardiovascular surgery or reintervention related to the device through procedure exit.

    Time frame: Measured at Day 0 (Procedure Exit)

  3. Number of participants Achieving Device Success

    Number of patients achieving successful deployment and correct anatomical positioning of the device, absence of procedural mortality or stroke, and freedom from unplanned surgical or interventional procedures related to the device through 30 days.

    Time frame: 30 Days

Secondary outcomes

  1. Number of Participants by Mitral Regurgitation (MR) Severity Grade

    Assessment of MR severity evaluated by transthoracic/transesophageal echocardiography (TTE/TEE). MR severity is categorized using standard clinical grading: Grade 0 (None/Trace), Grade 1+ (Mild), Grade 2+ (Moderate), Grade 3+ (Severe), and Grade 4+ (Very Severe). Higher grades indicate worse outcome severity.

    Time frame: 30 Days

  2. Number of Participants Experiencing Major Adverse Events (MAE)

    Occurrence of serious cardiovascular, cerebrovascular, or renal events related to the device or procedure.

    Time frame: 30 Days

07

Study locations

1 of 1 sites recruiting
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Start is estimated for Aug 2026; primary completion for Apr 2032, 68 months later.

Of 91 industry-sponsored interventional studies with no phase under Mitral Valve Insufficiency, half reached primary completion within 59 months of starting (the median), counting those still running; a quarter within 25 and three quarters within 144. This study's planned 68 months is above that.

Counting every sponsor, half of 144 studies reached it within 56 months; a quarter within 25 and three quarters within 108.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 9, 2026
First posted
Mar 13, 2026
StartEst.
Aug 2026
Primary completionEst.
Apr 2032
CompletionEst.
Apr 2032
Last update
Aug 19, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Aug 19, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07470788
Lead sponsor
Vesalius Cardiovascular Inc.
Responsible party
Sponsor
First posted
Mar 13, 2026
Start date
Aug 2026 (estimated)
Primary completion
Apr 2032 (estimated)
Completion
Apr 2032 (estimated)
Last update
Aug 19, 2026

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

No contact was published for this record. The registry link below has the sponsor’s details.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion